Your account is not claimed yet. You can sign up with ORCID to claim your account.

Richard B Kim (R B Kim)

ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 19

Top Venues

Alimentary pharmacology & therapeutics

Molecular pharmaceutics

Breast cancer research and treatment

Annals of internal medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Ute I Schwarz, Morgan Woldanski-Travaglini, Valerie Swanston, Mariam Mikhail, Chantel Cacciotti, Elizabeth Cairney, Serina Patel, Jennifer Seelisch, Soumitra Tole, Marta Wilejto, Rommel G Tirona, Richard B Kim, Alexandra P Zorzi
TPMT intermediate metabolizer status and thiopurine-associated toxicity during maintenance therapy in childhood acute lymphoblastic leukemia. Clinical pharmacology and therapeutics (2023)
Samantha Medwid, Theodore J Wigle, Cameron Ross, Richard B Kim
Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction. International journal of molecular sciences 24 (17) (2023)
Samantha Medwid, Theodore J Wigle, Richard B Kim
Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype. Cancer chemotherapy and pharmacology (2022)
Samantha Medwid, Richard B Kim
Implementation of Pharmacogenomics- Where are we now? British journal of clinical pharmacology (2022)
Eugene Brailovski, Richard B Kim, David Juurlink
Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment. Annals of internal medicine 174 (3) (2021)
Laura E Russell, Marianne K DeGorter, Richard H Ho, Brenda F Leake, Crystal L Schmerk, Sara E Mansell, Richard B Kim
Mouse NTCP-Mediated Rosuvastatin Uptake In Vitro and in Slc10a1-Deficient Mice. The AAPS journal 23 (1) (2021)
Mathushan Subasri, David Barrett, Jovana Sibalija, Lisa Bitacola, Richard B Kim
Pharmacogenomic-based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system. Clinical and translational science 14 (6) (2021)
Aze Suzanne Wilson, Richard B Kim
Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-α antagonist immunogenicity - does location matter? Alimentary pharmacology & therapeutics 53 (9) (2021)
Eugene Brailovski, Richard B Kim, David Juurlink
Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of internal medicine 173 (7) (2020)
Laura E Russell, Yitian Zhou, Volker Martin Lauschke, Richard B Kim
In Vitro Functional Characterization and in Silico Prediction of Rare Genetic Variation in the Bile Acid and Drug Transporter, Na+-Taurocholate Cotransporting Polypeptide (NTCP, SLC10A1). Molecular pharmaceutics 17 (4) (2020)
Adrienne E Borrie, Finnley A Rose, Yun-Hee Choi, Francisco E Perera, Nancy Read, Tracy Sexton, Michael Lock, Theodore A Vandenberg, Karin Hahn, Jawaid Younus, Diane Logan, Kylea Potvin, Brian Yaremko, Edward Yu, John Lenehan, Stephen Welch, Wendy A Teft, Richard B Kim
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. Breast cancer research and treatment 183 (2) (2020)
Aze Suzanne Wilson, Celeste Peel, Qian Wang, A Demetri Pananos, Richard B Kim
Letter: immunogenicity of infliximab-ready for routine prediction? Authors' reply. Alimentary pharmacology & therapeutics 51 (8) (2020)
Aze Suzanne Wilson, Celeste Peel, Qian Wang, Athanasios Demetri Pananos, Richard B Kim
HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. Alimentary pharmacology & therapeutics 51 (3) (2019)
Aze Wilson, Bradley L Urquhart, Terry Ponich, Nilesh Chande, James C Gregor, Melanie Beaton, Richard B Kim
Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression. Molecular pharmaceutics 16 (9) (2019)
A Wilson, L E Jansen, R V Rose, J C Gregor, T Ponich, N Chande, R Khanna, B Yan, V Jairath, N Khanna, M Sey, M Beaton, K McIntosh, W A Teft, Richard B Kim
Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors' reply. Alimentary pharmacology & therapeutics 47 (7) (2019)
Laura E Jansen, Wendy A Teft, Rhiannon V Rose, Daniel J Lizotte, Richard B Kim
CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy. Breast cancer research and treatment 171 (3) (2018)
Adrienne E Borrie, Rhiannon V Rose, Yun-Hee Choi, Francisco E Perera, Nancy Read, Tracy Sexton, Michael Lock, Theodore A Vandenberg, Karin Hahn, Robert Dinniwell, Jawaid Younus, Diane Logan, Kylea Potvin, Brian Yaremko, Edward Yu, John Lenehan, Stephen Welch, Rachel F Tyndale, Wendy A Teft, Richard B Kim
Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast cancer research and treatment 172 (2) (2018)
A Wilson, L E Jansen, R V Rose, J C Gregor, T Ponich, N Chande, R Khanna, B Yan, V Jairath, N Khanna, M Sey, M Beaton, K McIntosh, W A Teft, Richard B Kim
HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 47 (5) (2017)
Wendy A Teft, Bridget L Morse, Brenda F Leake, Aze Wilson, Sara E Mansell, Robert A Hegele, Richard H Ho, Richard B Kim
Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. Molecular pharmaceutics 14 (1) (2016)

Richard B Kim.css-eqlu8i{font-size:small;padding-left:4px;} (R B Kim)

Publication Activity (10 Years)

Top Topics

Top Venues

Richard B Kim (R B Kim)